Autoantibodies Binding to Citrullinated Telopeptide of Type II Collagen and to Cyclic Citrullinated Peptides Predict Synergistically the Development of Seropositive Rheumatoid Arthritis
Overview
Authors
Affiliations
Objectives: To find out whether autoantibodies to citrullinated telopeptides of type I and II collagens and to cyclic citrullinated peptides (CCPs) predict the development of rheumatoid arthritis (RA).
Methods: A case-control study (matched for sex, age and municipality) was nested within a Finnish cohort of 19072 adults who had neither arthritis nor a history of it at the baseline examination during 1973-7. 124 subjects developed RA by late 1989, and of these, 89 were positive for rheumatoid factor (RF). Preillness serum specimens were analysed for autoantibodies against arginine (A)- or citrulline (C)-containing synthetic telopeptides using a chemiluminescence method and for anti-CCPs Mark2 with an enzyme-linked immunosorbent assay method.
Results: The mean levels of autoantibodies to citrulline-containing telopeptides and the C/A ratios of type I and II collagens and to CCP were higher in subjects who later developed RF-positive RA. In the highest tertiles of C/A (I), C/A (II) ratios and anti-CCPs levels, the relative risk of RF-positive RA was significantly increased. In the multifactorial model, only anti-CCPs retained its statistical significance. However, the interaction term of C/A (II) ratio and anti-CCPs proved to be statistically significant (p = 0.02). The subjects ranked into the highest tertiles of both C/A (II) ratio and anti-CCPs had an odds ratio of 20.06 (95% confidence interval, 4.37 to 92.06) of developing RF-positive RA compared with those in the lowest tertiles of these antibodies. None of the autoantibodies predicted RF-negative RA.
Conclusion: Autoantibodies to citrullinated telopeptides of type I and II collagen and to CCPs exert a synergistic effect on the risk of seropositive RA.
Engineered T cells and their therapeutic applications in autoimmune diseases.
Bao L, Bo X, Cao H, Qian C, Wang Z, Li B Zool Res. 2022; 43(2):150-165.
PMID: 35008131 PMC: 8920845. DOI: 10.24272/j.issn.2095-8137.2021.363.
Ikeda T, Nakamura K, Kida T, Oku H Graefes Arch Clin Exp Ophthalmol. 2021; 260(2):387-403.
PMID: 34379187 PMC: 8786754. DOI: 10.1007/s00417-021-05342-6.
Gilbert B, Lamacchia C, Mongin D, Lauper K, Trunk E, Studer O BMJ Open. 2021; 11(7):e048409.
PMID: 34261688 PMC: 8280908. DOI: 10.1136/bmjopen-2020-048409.
Turunen S, Hannonen P, Koivula M, Risteli L, Risteli J Arthritis Res Ther. 2015; 17:2.
PMID: 25573503 PMC: 4320812. DOI: 10.1186/s13075-014-0515-z.
Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.
Kelkka T, Kienhofer D, Hoffmann M, Linja M, Wing K, Sareila O Antioxid Redox Signal. 2014; 21(16):2231-45.
PMID: 24787605 PMC: 4224049. DOI: 10.1089/ars.2013.5828.